Average Diluted Shares Outstanding: 243 million, 1% lower than a year ago. Cardinal Health Inc (NYSE:CAH) reported strong second quarter results, driven by robust demand in pharmaceutical and ...

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...

Maria is best known for her work on steroid 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH). Most of her fellows and trainees in the late 1970s and early 1980s ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Cardinal Health (CAH) reports results for the quarter ended December 2024. While this widely-known consensus outlook ...

related to benign prostatic hyperplasia. Materials and methods: In this open-label trial, 12 male patients (median age 67 years) with an I-PSS >15 (median 16) and maximum urinary flow (Q max ...

One company to watch right now is Cardinal Health (CAH). CAH is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 15.28. This compares to its ...